-
1.发明授权Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier 有权抗人CCR7抗体，杂交瘤，核酸，载体，细胞，药物组合物和抗体固定载体公开(公告)号：US09505844B2
公开(公告)日：2016-11-29
申请号：US14489898
申请日：2014-09-18
发明人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
IPC分类号： C07K16/28 , A61K31/713 , A61K39/00
CPC分类号： C07K16/2866 , A61K31/713 , A61K2039/505 , C07K2317/70 , C07K2317/76
摘要： An anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like is described. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.
摘要翻译： 描述可用作组织纤维化或癌症治疗剂的抗人CC-motif-receptor-7（抗人CCR7）抗体和含有抗人CCR7抗体的药物组合物等 。 特异性结合人CCR7细胞外结构域的抗人CCR7抗体，其具有含有SEQ ID NO：7，SEQ ID NO：17，SEQ ID NO：27，SEQ ID NO：17，SEQ ID NO：27，SEQ ID NO：17所示氨基酸序列的重链CDR3。 提供了37，SEQ ID NO：47，SEQ ID NO：57，SEQ ID NO：67或SEQ ID NO：77。 还提供了具有重链CDR 1-3的抗人CCR7抗体和含有由SEQ ID NO：5-10，15-20,25-30,35-40,45表示的氨基酸序列的轻链CDR 1-3 -50,55-60,65-70或75-80。 本发明的抗人CCR7抗体可以用作组织纤维化或癌症治疗剂的活性成分。
-
公开(公告)号：US11357787B2
公开(公告)日：2022-06-14
申请号：US17431268
申请日：2020-02-17
发明人： Masami Ashida , Yuji Urushibata , Kiyoshi Takayama
IPC分类号： A61K31/7088 , A61P37/04 , C07K16/28 , C12N5/12 , C12N15/62 , C12N15/85 , C12P21/02 , G01N33/533
摘要： To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.
-
公开(公告)号：US20190389949A1
公开(公告)日：2019-12-26
申请号：US16555524
申请日：2019-08-29
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
-
公开(公告)号：US20160075780A1
公开(公告)日：2016-03-17
申请号：US14864707
申请日：2015-09-24
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , C07K16/2869 , C07K17/00 , C07K2317/24 , C07K2317/76 , G01N33/88
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
-
公开(公告)号：US11649281B2
公开(公告)日：2023-05-16
申请号：US16555524
申请日：2019-08-29
CPC分类号： C07K16/28 , C07K16/2869 , C07K17/00 , G01N33/88 , C07K2317/24 , C07K2317/76
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
-
公开(公告)号：US10435465B2
公开(公告)日：2019-10-08
申请号：US14864707
申请日：2015-09-24
IPC分类号： A61K39/395 , C07K16/28 , C07K17/00 , G01N33/88
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.021 秒)
